Plain-English translation of NCT07067463 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help slow the worsening of primary progressive multiple sclerosis (PPMS). About 705 people will participate worldwide, with some receiving the medication and others receiving a placebo (an inactive pill). Researchers want to understand whether this treatment can reduce disability progression over time.
Primary progressive multiple sclerosis causes steady worsening of disability over time, and there are limited treatment options available for this form of MS. This study is designed to find out whether this medication might help slow that progression and improve outcomes for people living with PPMS.
You likely qualify if…
You likely don't qualify if…
You would take either the new medication or a placebo pill regularly for 1 to 5 years, with frequent study visits to monitor your health and disability progression through physical exams and tests. About two-thirds of participants will receive the active medication, while one-third will receive placebo, and neither you nor the researchers will know which group you're in. You'll need to be willing to commit to regular follow-up appointments and avoid certain other medications and vaccines during your participation.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States